Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
FOLD Amicus Therapeutics, Inc. daily Stock Chart
FOLD [NASD]
Amicus Therapeutics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-1.47 Insider Own0.80% Shs Outstand159.11M Perf Week10.36%
Market Cap2.37B Forward P/E- EPS next Y-0.91 Insider Trans110.79% Shs Float159.11M Perf Month20.23%
Income-208.40M PEG- EPS next Q-0.31 Inst Own- Short Float21.23% Perf Quarter50.10%
Sales16.30M P/S145.64 EPS this Y-23.80% Inst Trans3.19% Short Ratio8.60 Perf Half Y111.03%
Book/sh1.87 P/B7.98 EPS next Y21.90% ROA-21.40% Target Price16.50 Perf Year89.10%
Cash/sh1.43 P/C10.45 EPS next 5Y60.80% ROE-65.40% 52W Range4.41 - 14.36 Perf YTD200.20%
Dividend- P/FCF- EPS past 5Y-3.00% ROI-37.20% 52W High3.86% Beta1.82
Dividend %- Quick Ratio2.40 Sales past 5Y-25.40% Gross Margin83.60% 52W Low238.32% ATR0.55
Employees263 Current Ratio2.40 Sales Q/Q- Oper. Margin- RSI (14)65.71 Volatility4.21% 3.98%
OptionableYes Debt/Eq0.60 EPS Q/Q14.90% Profit Margin- Rel Volume1.54 Prev Close13.96
ShortableYes LT Debt/Eq0.60 EarningsAug 07 BMO Payout- Avg Volume3.93M Price14.92
Recom1.50 SMA209.44% SMA5012.56% SMA20073.51% Volume6,066,841 Change6.88%
Sep-13-17Reiterated Chardan Capital Markets Buy $17.50 → $16.50
Aug-10-17Reiterated Chardan Capital Markets Buy $12.50 → $17.50
Jan-24-17Upgrade Robert W. Baird Neutral → Outperform $7 → $10
May-18-16Initiated BofA/Merrill Buy $10
Apr-14-16Initiated Robert W. Baird Neutral $9
Apr-12-16Reiterated Chardan Capital Markets Buy $10 → $15
Sep-16-15Downgrade Chardan Capital Markets Buy → Neutral $17
Jun-16-15Reiterated Chardan Capital Markets Buy $14 → $17.50
May-29-15Initiated Chardan Capital Markets Buy $14
Dec-20-12Reiterated Canaccord Genuity Buy $11 → $6
Dec-20-12Downgrade Capstone Investments Buy → Hold $3
Nov-01-12Initiated Capstone Investments Buy $7
Apr-06-10Initiated Canaccord Adams Buy
Mar-31-10Initiated Leerink Swann Mkt Perform
Oct-05-09Downgrade Wedbush Morgan Outperform → Underperform $17 → $3.50
Mar-20-09Initiated Wedbush Morgan Buy $17
Feb-27-09Reiterated Lazard Capital Buy $18 → $15
Jul-23-08Reiterated Lazard Capital Buy $13 → $21
May-14-08Reiterated Lazard Capital Buy $15 → $13
Jan-04-08Reiterated Lazard Capital Buy $18 → $15
Sep-20-17 04:01PM  Amicus Therapeutics to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology GlobeNewswire +6.88%
11:26AM  Harry Boxers five stocks to watch today MarketWatch
Sep-19-17 07:30AM  U.S. FDA Grants Fast Track Designation for Amicus Therapeutics Migalastat for Treatment of Fabry Disease GlobeNewswire
Sep-18-17 02:04AM  [$$] Clinical Development News, Sept. 11-15 The Wall Street Journal
Sep-15-17 07:40AM  Corporate News Blog - Amicus Therapeutics Reports Phase-3 Results for Sd-101 in Epidermolysis Bullosa did not Meet Primary Endpoints ACCESSWIRE
Sep-14-17 04:01PM  Amicus Therapeutics Announces Approval for Galafold (Migalastat) for Treatment of Fabry Disease in Canada GlobeNewswire
Sep-13-17 11:35AM  Amicus abandons wound treatment, focus shifts to future trial data Reuters
08:32AM  A father's fight to find a cure for his children's rare disease Fox Business Videos
06:21AM  Amicus Therapeutics' wound treatment fails late-stage trial Reuters
06:00AM  Amicus Therapeutics Announces Top-Line Phase 3 Results for SD-101 in Epidermolysis Bullosa GlobeNewswire
Sep-12-17 08:56AM  Options Traders Expect Huge Moves in Amicus Therapeutics (FOLD) Stock Zacks
Sep-10-17 08:31AM  Is Amicus Therapeutics Stock Still a Strong Buy? Motley Fool
Sep-08-17 10:09AM  Time to Bring Amicus Therapeutics Into the 'FOLD' TheStreet.com
Aug-25-17 07:30AM  Amicus Therapeutics to Highlight Fabry Disease Program at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) GlobeNewswire
Aug-21-17 08:10AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics Inc. and Ritter Pharmaceuticals Inc. ACCESSWIRE
Aug-20-17 09:17PM  [$$] Clinical Development News, Aug. 14-18 The Wall Street Journal
Aug-15-17 04:01PM  Amicus Therapeutics Announces Approval for Galafold (Migalastat) for Treatment of Fabry Disease in Australia GlobeNewswire
Aug-12-17 06:01AM  Edited Transcript of FOLD earnings conference call or presentation 7-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 03:07PM  The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July Motley Fool -5.91%
Aug-07-17 11:57PM  Amicus Therapeutics reports 2Q loss Associated Press +5.06%
07:00AM  Amicus Therapeutics Announces Second Quarter 2017 Financial Results and Corporate Updates GlobeNewswire
06:10AM  Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 07:30AM  Amicus Therapeutics to Announce Second Quarter 2017 Financial Results on August 7, 2017 GlobeNewswire
Jul-19-17 12:54PM  4 Momentum Plays To Watch Forbes
Jul-18-17 07:30AM  Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares GlobeNewswire +6.97%
Jul-13-17 09:01PM  No Surprise! Amicus Therapeutics Hits Up Investors for More Cash Motley Fool
09:28AM  This $3 Biotech Stock Is Making an 11% Move Thursday TheStreet.com
Jul-12-17 04:01PM  Amicus Therapeutics Announces Public Offering of Common Stock GlobeNewswire
10:25AM  Company News for July 12, 2017 Zacks
09:39AM  Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Amicus Therapeutics, Inc. and NovoCure Ltd. Accesswire
07:30AM  One FDA About-Face Doesn't Mean an Orphan-Drug Bonanza Bloomberg
12:40AM  [$$] Amicus Therapeutics Gets Nod From FDA to Submit Experimental Drug for Approval The Wall Street Journal
Jul-11-17 08:39PM  Arena Pharma's Stock Could Still Double Even After Tuesday's Epic Run TheStreet.com +25.93%
06:01PM  How Big Is Amicus Therapeutics Galafold Opportunity in The U.S.? Motley Fool
04:57PM  These Small Biotechs Are Leading The Pack Today Here's Why Investor's Business Daily
04:35PM  Why Halcon Resources, Amicus Therapeutics, and Rent-A-Center Jumped Today Motley Fool
01:13PM  Why Amicus Therapeutics, Inc. (FOLD) Stock Is Soaring Today InvestorPlace
12:53PM  Why Amicus Therapeutics Inc. Rocketed Higher Today Motley Fool
12:51PM  Story Stocks from Briefing.com Briefing.com
11:44AM  Amicus jumps 28 percent after FDA speeds approval process... CNBC Videos
09:43AM  Stocks Open Mixed: This Biotech Soars 42%; Snap, Blue Apron Fold Investor's Business Daily
07:58AM  Amicus Therapeutics's stock soars on heavy volume after FDA clears NDA submission for Fabry disease treatment MarketWatch
06:00AM  U.S. FDA Confirms Amicus Therapeutics May Submit New Drug Application for Migalastat for Fabry Disease GlobeNewswire
06:00AM  FDA Reverses Decision, Allowing Amicus To File For Rare Disease Drug Forbes
Jun-28-17 07:30AM  Amicus Therapeutics Submits Japanese New Drug Application for Migalastat for Fabry Disease GlobeNewswire
Jun-19-17 08:37AM  Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 7.3% Zacks
Jun-14-17 10:28AM  Amicus Therapeutics: Is This Biotech an Orphan Underdog? Motley Fool
Jun-07-17 07:30AM  Amicus Therapeutics to Present at Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
Jun-06-17 11:12AM  Here's Why Amicus Therapeutics Stock Edged Higher in May Motley Fool
Jun-03-17 09:01AM  3 Stocks With Vertex Pharmaceuticals-Like Return Potential Motley Fool
May-31-17 07:30AM  Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa GlobeNewswire
May-19-17 07:30AM  Amicus Therapeutics Announces Planned Analysis of Primary Endpoints in Phase 3 Epidermolysis Bullosa Study GlobeNewswire
May-18-17 08:00AM  Today's Research Reports on Biotech Stocks to Watch: Exelixis and Amicus Therapeutics Accesswire
May-15-17 07:00AM  Amicus Therapeutics Announces Positive Functional Data from Initial Patients in Pompe Phase 1/2 Study GlobeNewswire
May-10-17 08:36AM  Edited Transcript of FOLD earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
07:30AM  Amicus Therapeutics to Present at Two Upcoming Investor Conferences GlobeNewswire
May-09-17 04:37PM  ETFs with exposure to Amicus Therapeutics, Inc. : May 9, 2017 Capital Cube
08:57AM  Amicus Therapeutics reports 1Q loss Associated Press
08:15AM  Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call Accesswire
07:30AM  Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates GlobeNewswire
May-08-17 05:53PM  Amicus Therapeutics, Inc. Value Analysis (NASDAQ:FOLD) : May 8, 2017 Capital Cube
May-05-17 08:56AM  Amicus Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : FOLD-US : May 5, 2017 Capital Cube
May-02-17 04:01PM  Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017 GlobeNewswire
07:30AM  Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in France GlobeNewswire
Apr-06-17 08:15AM  Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day GlobeNewswire
Apr-03-17 08:01AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Amicus Therapeutics Completes Enrollment in ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study GlobeNewswire
Mar-17-17 09:30AM  Today's Research Reports on Biotech Stocks to Watch: Amicus Therapeutics and Sarepta Therapeutics Accesswire
Mar-16-17 10:41AM  Are These 2 Biotechs Diamonds in the Rough? Motley Fool
Mar-08-17 04:01PM  Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Italy GlobeNewswire
07:47AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-07-17 01:55PM  Harry Boxers six biotechnology stocks to watch MarketWatch -8.84%
01:04PM  AMICUS THERAPEUTICS INC Financials
Mar-03-17 09:09AM  Four biotech stocks surging on optimism about drug trials, product launches MarketWatch
Mar-02-17 03:34PM  Biotechs Breaking Out On Drug Development News Forbes
01:15PM  Amicus Therapeutics, Inc. (FOLD) Could Be The Force That Brings Change To The FDA Insider Monkey
09:30AM  Dow Soars Above 21,000 for the First Time in History: Today's Reports on Clean Energy Fuels and Amicus Therapeutics Accesswire
07:30AM  Amicus Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Mar-01-17 11:22PM  Edited Transcript of FOLD earnings conference call or presentation 1-Mar-17 1:30pm GMT +17.10%
06:43PM  Pompe drug lauded by Trump costs $300,000 a year Reuters
05:51PM  Trump's latest comments are 'constructive' for drug industry: Amicus Therapeutics CEO at CNBC
04:52PM  Amicus Therapeutics CEO: Trump constructive for our indus...
04:50PM  Why Amicus Therapeutics, Inc. Jumped Higher Today at Motley Fool
11:35AM  4 Biopharma Stocks Moving the Market on Wednesday
10:38AM  Trump wants to upend the 'slow and burdensome' drug approval process at the FDA here's what the agency actually does
09:16AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
08:12AM  Amicus CEO John Crowley, Not His Daughter Megan, Might Compel Trump to Make Big Changes at FDA
07:07AM  Q4 2016 Amicus Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Amicus Therapeutics Announces Full-Year 2016 Financial Results and Corporate Updates GlobeNewswire
Feb-28-17 09:55AM  Amicus Therapeutics Launches Galafold in UK at Investopedia
Feb-27-17 08:00AM  Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in the United Kingdom GlobeNewswire +7.89%
Feb-23-17 09:30AM  Could 2017 Prove to be a Bull Market for Biotechs? Today's Reports on Depomed and Amicus Therapeutics Accesswire
06:00AM  These Small Biotechs Are Poised to Go Higher at Investopedia
Feb-22-17 05:36PM  Amicus Therapeutics to Announce Full-Year 2016 Financial Results and Corporate Updates on March 1, 2017 GlobeNewswire
Feb-16-17 07:17AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-15-17 07:30PM  Amicus Therapeutics Presents Additional Positive Preliminary Phase 1/2 Data at WORLDSymposium 2017 GlobeNewswire
12:49PM  Amicus Therapeutics Updates Migalastat Drug at Investopedia
08:42AM  AMICUS THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Amicus Therapeutics Presents Important New Scientific Findings and Preclinical Data for Pompe Program at WORLDSymposium 2017 GlobeNewswire
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its principal product is the migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which has completed two global Phase III registration studies. The company is also developing SD-101, which is in Phase III clinical study for the treatment of the genetic connective tissue disorder epidermolysis bullosa; and AT3375 to treat Parkinson's disease. It is conducting a Phase 1/2 clinical study of ATB200-02 to investigate pompe treatment paradigm in pompe patients. The company has strategic alliance with GlaxoSmithKline plc to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerJul 13Buy12.251,500,00018,375,00017,888,597Jul 14 08:30 AM
Barth JayChief Medical OfficerJun 19Option Exercise10.0030,000300,00094,184Jun 19 04:07 PM
Barth JayChief Medical OfficerJun 19Sale10.0030,000300,00064,184Jun 19 04:07 PM
Do HungChief Science OfficerMay 19Sale8.0029,914239,312474,438May 23 06:14 PM
Do HungChief Science OfficerMay 15Sale8.0029,914239,312504,352May 17 05:00 PM
Campbell Bradley LChief Operating OfficerMar 02Sale8.0049,050392,400127,475Mar 03 07:25 PM
Do HungChief Science OfficerFeb 07Sale6.0025,000150,000534,266Feb 09 04:35 PM
Do HungChief Science OfficerJan 13Sale6.0025,000150,000559,266Jan 17 04:14 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 30Buy4.9694,750470,05516,293,847Jan 04 02:25 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 29Buy4.8594,750459,91716,293,847Dec 30 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 28Buy4.9147,375232,70616,199,097Dec 30 08:45 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 23Buy4.8185,275410,05016,151,722Dec 27 10:57 AM
PERCEPTIVE ADVISORS LLC10% OwnerDec 22Buy4.51189,500854,83516,066,447Dec 23 08:31 AM
Quimi DaphneSVP, FinanceNov 09Option Exercise8.002,85822,86427,047Nov 10 04:07 PM
Quimi DaphneSVP, FinanceNov 09Sale8.008,54668,36824,189Nov 10 04:07 PM
Do HungChief Science OfficerNov 01Sale7.0025,000175,000533,453Nov 03 04:07 PM
Do HungChief Science OfficerOct 03Sale7.2525,000181,250558,453Oct 04 08:21 PM
open in yahoo | open in reuters | open in google